Howard M Fillit, MD

Locations

Howard Fillit, M.D.

57 West 57th Street, Suite 904, New York, NY, 10019

212-901-7980

Insurance Information

Accepted insurance may vary by the doctor’s office location. Please contact the office directly to obtain the most up-to-date insurance information.

Physicians who provide services at hospitals and facilities in the Mount Sinai Health System might not participate in the same health plans as those Mount Sinai hospitals and facilities (even if the physicians are employed or contracted by those hospitals or facilities).

Information regarding insurance participation and billing by this physician may be found on this page, and can also be obtained by contacting this provider directly. Because physicians insurance participation can change, the insurance information on this page may not always be up-to-date. Please contact this physician directly to obtain the most up-to-date insurance information.

Insurance and health plan networks that the various Mount Sinai Health System hospitals and facilities participate in can be found on the Mount Sinai Health System website.

Publications

Scopus h-index:50

Article:177

Review Article:40

Comment/Debate:10

Letter:6

Editorial:17

Chapter:3

Recent Artifacts

• Alzheimer's disease medication use and adherence patterns by race and ethnicity
• Toward comprehensive value assessment for Alzheimer's disease innovations
• Recommendations to address key recruitment challenges of Alzheimer's disease clinical trials
• Author Correction: FAM222A encodes a protein which accumulates in plaques in Alzheimer’s disease (Nature Communications, (2020), 11, 1, (411), 10.1038/s41467-019-13962-0)
• End-of-life burdensome interventions among Medicare fee-for-service beneficiaries with no dementia, non-advanced dementia, and advanced dementia
• The trend of disruption in the functional brain network topology of Alzheimer’s disease
• Blood Biomarkers from Research Use to Clinical Practice: What Must Be Done? A Report from the EU/US CTAD Task Force
• Glucose metabolism patterns: A potential index to characterize brain ageing and predict high conversion risk into cognitive impairment
• An IL1RL1 genetic variant lowers soluble ST2 levels and the risk effects of APOE-ε4 in female patients with Alzheimer’s disease
• Standardizing Electronic Health Record Data on AD/ADRD to Accelerate Health Equity in Prevention, Detection, and Treatment

Industry Relationships

Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device and biotechnology companies to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their relationships with such companies.

Below are financial relationships with industry reported by Dr. Fillit during 2022 and/or 2023. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.

Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.